Vanguard Capital Management’s Climb Bio CLYM Stock Holding History
Bought
Maintained
Sold
Other funds holding CLYM
Vanguard Capital Management's CLYM Position: Q3 2026 in Review
Vanguard Capital Management increased its Climb Bio (CLYM) stake by 40% in Q3 2026, buying an estimated $9.44M and bringing the position to 2,375,933 shares worth $27.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2225.
Vanguard Capital Management first reported a position in CLYM in Q1 2026 and has held it in 3 quarters since. 128 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.
- Vanguard Capital Management held 2,375,933 shares of Climb Bio worth $27.3M as of Q3 2026.
- Vanguard Capital Management bought 677,279 Climb Bio shares in Q3 2026, an estimated $9.44M.
- Climb Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2225 holding.
- Vanguard Capital Management first reported a position in Climb Bio in Q1 2026 and has held it in 3 quarters since.
- 128 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.